Interleukin-6 production and secretion by human parathyroids

Clinical and Experimental Immunology

Volumn 136, Issue 1, 2004, Pages 145-156

  Safley, S A ^a,b   Villinger, F ^a   Jackson, E H ^a   Tucker Burden, C ^a   Cohen, C ^a   Weber, C J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b 5207 Woodruff Memorial Building ^*  (United States)

Author keywords

Cytokines; Hyperparathyroidism; Interleukin 6; Parathyroid; Parathyroid hormone

Indexed keywords

CHROMOGRANIN A; INTERLEUKIN 6; PARATHYROID HORMONE;

ADRENAL GLAND; ARTICLE; CELL PROLIFERATION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; OSTEOBLAST; OSTEOLYSIS; PARATHYROID GLAND; PARATHYROID TUMOR; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

CELLS, CULTURED; CHROMOGRANIN A; CHROMOGRANINS; HUMANS; HYPERPARATHYROIDISM; INTERLEUKIN-6; MICROSCOPY, CONFOCAL; OSTEOBLASTS; PARATHYROID GLANDS; PARATHYROID HORMONE; PARATHYROID NEOPLASMS; PRECANCEROUS CONDITIONS; RNA, MESSENGER; VON WILLEBRAND FACTOR;

EID: 1842559536     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02419.x     Document Type: Article

References (45)

1. Silverberg SJ, Bilezikian J. Clinical presentation of primary hyperparathyroidism in the United States. In: Bilezikian J, Marcus R, Levine M, eds. The parathyroids: basic and clinical concepts, 2nd edn. New York: Academic Press, 2001:349-60.
2. Silverberg S, Shane E, Jacobs T, Siris E, Bilezikian J. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999; 341:1249-55.
3. Kulak C, Bandeira C, Voss D, Sobieszczyk S, Silverberg S, Bandeira F. Marked improvement in bone mass after parathyroidectomy in osteitis fibrosa cystica. J Clin Endocrinol Metab 1998; 83:732-5.
4. Silverberg S, Bilezikian J. Cytokines in primary hyperparathyroidism - factors that matter [Editorial]. J Clin Endocrinol Metab 1996; 81:3448-9.
5. Greenfield E, Shaw S, Gornik S, Banks M. Adenyl cyclase and interleukin 6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption. J Clin Invest 1995; 96:1238-44.
6. Ishimi Y, Miyaura C, Jin C et al. IL-6 is produced by osteoblasts and induces bone resporption. J Immunol 1990; 145:3297-303.
7. Rifas L, Kenney J, Marcelli M et al. Production of interleukin-6 in human osteoblasts and human bone marrow stromal cells: evidence that induction by interleukin-1 and tumor necrosis factor-α is not regulated by ovarian steroids. Endocrinology 1995; 136:4056-67.
8. Horowitz M, Brown M, Insogna K et al. PTHrP and PTH induce the secretion of IL-6 by a clonal osteosarcoma cell line. In: Molecular and cellular biology of cytokines. New York: Wiley-Liss, Inc., 1990: 471-6.
9. Nakchbandi IA, Mitnick MA, Masiukiewicz US, Sun BH, Insogna KL. IL-6 negatively regulated IL-11 production in vitro and in vivo. Endocrinology 2001; 142:3850-6.
10. Lowik C, van der Plujm G, Hoekman K, Bijvoet O, Aarden L, Papapoulos S. Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochem Biophys Res Commun 1989; 162:1546-52.
11. Greenfield E, Gornik S, Horowitz M, Donahue H, Shaw S. Regulation of cytokine expression in osteoblasts by parathyroid hormone: rapid stimulation of interleukin-6 and leukemia inhibitory factor mRNA. J Bone Miner Res 1993; 8:1163-71.
12. Li N, Ouchi Y, Okamoto Y et al. Effect of parathyroid hormone on release of interleukin-1 and interleukin-6 from cultured mouse osteoblastic cells. Biochem Biophys Res Commun 1991; 179:236-42.
13. Sakagami Y, Girasole G, Yu X-P, Boswell H, Manolagas S. Stimulation of interleukin-6 production by either calcitonin gene-related peptide or parathyroid hormone in two phenotypically distinct bone marrow-derived murine stromal cell lines. J Bone Miner Res 1993; 8:811-6.
14. Jilka R, Hangoc G, Girasole G et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992; 257:88-91.
15. Jacob T, Mitnick M, Shapses S, Ellison A, Gundberg C, Insogna K. Circulating levels of interleukin-6 and tumor necrosis factor-a are elevated in primary hyperparathyroidism and correlate with markers of bone resporption - a clinical research center study. J Clin Endocrinol Metab 1996; 81:3450-4.
16. Insogna K, Mitnick MA, Pascarella J, Nakchbandi I, Grey A, Masiukiewicz U. Role of the interleukin-6/interleukin-6 soluble receptor cytokine system in mediating increased skeletal sensitivity to parathyroid hormone in perimenopausal women. J Bone Miner Res 2002; 17:N108-N116.
17. Nakchbandi IA, Mitnick MA, Lang R, Gundberg C, Kinder B, Insogna K. Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2002; 87:4946-51.
18. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993; 54:1-79.
19. Wang L, Chow K, Wu C. Expression and up-regulation of interleukin-6 in oesophageal carcinoma cells by n-sodium butyrate. Br J Cancer 1999; 80:1617-22.
20. Mori S, Murakami-Mori K, Bonavida B. Dexamethasone enhances expression of membrane and soluble interleukin-6 receptors by prostate carcinoma cell lines. Anticancer Res 1998; 18:4403-8.
21. Heese M, Dimitriades-Schmutz B, Roe-John S. Role of interleukin-6 and soluble IL-6 receptor in region-specific induction of astrocytic differentiation and neurotrophin expression. Glia 1999; 26:191-200.
22. Goydos J, Brumfield A, Frezza E, Booth A, Lotze M, Carty E. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma. Ann Surg 1998; 227:398-404.
23. Kontogeorgos G, Messini I, Kyrodimou E et al. Immunohistochemical localization of interleukin-6 in peripheral human endocrine glands. Endocrine 2002; 17:135-40.
24. Nussbaum SR, Zahradnik RJ, Lavigne JR et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1988; 33:1364-7.
25. Tzanno-Martins C, Futata E, Jorgetti V, Duarte AJ. Immune response in hemodialysis patients: is there any difference when low and high iPTH levels are compared? Clin Nephrol 2000; 54:22-9.
26. Villinger F, Rollin PE, Brar SS et al. Markedly elevated levels of interferon (IFN)-γ, IFN-α, interleukin (IL)-2, IL-10, and tumor necrosis factor-α asssociated with fatal Ebola virus infection. J Infect Dis 1999; 178:5188-5191.
27. Villinger F, Brar S, Mayne A, Chikkala N, Ansari AA. Comparative analysis of cytokine genes from nonhuman primates. J Immunol 1995; 155:3945-54.
28. Huffman SL, Crutcher JM, Puri SK et al. Sterile protection of monkeys against malaria after administration of interleukin-12. Nat Med 1997; 3:80-3.
29. Villinger F, Hunt D, Mayne A et al. Qualitative and quantitative studies of cytokines synthesized and secreted by non-human primate peripheral blood mononuclear cells. Cytokine 1993; 5:469-79.
30. Merlano M, Conte P, Scarsi P et al. Nonfunctioning parathyroid carcinoma. A case report. Tumori 1985; 71:193-6.
31. Hilbert DM, Kopf M, Mock BA, Kohler G, Rudikoff S. Interleukin 6 is essential for in vivo development of B lineage neoplasm. J Exp Med 1995; 182:243-8.
32. Lattanzio G, Libert C, Aquilina M et al. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. Am J Pathol 1997; 151:689-96.
33. Yoshizaki K, Mutsuda T, Nishimoto N et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989; 74:1360-7.
34. Beck JT, Hsu SM, Wijdenes J et al. Alleviation of systemic manifestation of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994; 330:602-5.
35. Tamura T, Udagawa N, Takahashi N et al. Soluble interleukin 6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci 1993; 90:11924-8.
36. Poli V, Balena R, Fattori E et al. Interleukin 6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 1994; 13:1189-96.
37. Scheidt-Nave C, Bismar H, Leidig-Brickner G et al. Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past monopause. J Clin Endocrinol Metab 2001; 86:2032-42.
38. Alonzi T, Fattori E, Lazzaro D et al. Interleukin-6 is required for the development of collagen-induced arthritis. J Exp Med 1998; 187:468.
39. Eugster HP, Frei K, Kopf M, Lassmann H, Fontana A. IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur J Immunol 1998; 28:2178-87.
40. Grey A, Mitnick MA, Masiukiewicz U et al. A role for interleukin-6 in parathyroid hormone-induced bone resorption in vivo. Endocrinology 1999; 140:4683-90.
41. Biffl WL, Moore EE, Moore FA, Peterson VM. Interleukin-6 and the injured patient. Marker of injury or mediator of inflammation? Ann Surg 1996; 224:647-64.
42. Kronenberg HM, Bringhurst FR, Segre GV, Potts JT. Parathyroid Hormone Biosynthesis and Metabolism. In: Bilezikian JP, Marcus R, Levine MA, eds. The parathyroids: basic and clinical concepts. New York: Academic Press, 2001:17-30.
43. Smogorzewski M, Massry SG. Defects in B-cell function and metabolism in uremia: role of parathyroid hormone. Kidney Int Suppl 2001; 78:S186-S189.
44. Klinger M, Alexiewicz JM, Linker-Israeli M et al. Effect of parathyroid hormone on human T cell activation. Kidney Int 1990; 37:1543-51.
45. Gaciong Z, Alexiewicz JM, Linker-Israeli M, Shulman IA, Pitts TO, Massry SG. Inhibition of immunoglobulin production by parathyroid hormone. Implications in chronic renal failure. Kidney Int 1991; 40:96-106.